Promethera names chair of board
This article was originally published in Scrip
Promethera Biosciences, a Belgian biotechnology company developing a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, has named Dr John Tchelingerian chair of its board of directors. Dr Tchelingerian is a serial entrepreneur and a private investor. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.